Navigation Links
Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium
Date:12/9/2008

ochemical staining (IHC), is associated with a clinical response of the primary tumor in women receiving neoadjuvant docetaxel-capecitabine chemotherapy for locally advanced breast cancer (Lead Author: Jeffrey Ross)

-- Dec. 14, 7:00 to 9:00 a.m., [Poster No. 6091], Survival outcome is similar for first-line chemotherapy with capecitabine or taxane for metastatic breast cancer (Lead Author: Gretchen Kimmick)

The majority of the 15 ex-U.S. abstracts being presented highlight Xeloda as a cornerstone of combination treatment. The remaining Xeloda abstract is a non-Roche sponsored study.

About XELODA (capecitabine)

Xeloda is the only FDA-approved oral chemotherapy for both metastatic breast cancer and adjuvant and metastatic colorectal cancer. Inactive in pill form, Xeloda is enzymatically activated within the body; when it comes into contact with a naturally occurring protein called thymidine phosphorylase, or TP, Xeloda is transformed into 5-FU, a cytotoxic (cell-killing) drug.

Because many cancers have higher levels of TP than does normal tissue, more 5-FU is delivered to the tumor than to other tissue.

A clinically important drug interaction between Xeloda and warfarin has been demonstrated; altered coagulation parameters and/or bleeding and death have been reported. Clinically significant increases in prothrombin time (PT) and INR have been observed within days to months after starting Xeloda, and infrequently within one month of stopping Xeloda. For patients receiving both drugs concomitantly, frequent monitoring of INR or PT is recommended. Age greater than 60 and a diagnosis of cancer independently predispose patients to an increased risk of coagulopathy.

Xeloda is contraindicated in patients who have a known hypersensitivity to 5-fluorouracil, and in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Xeloda is contraindic
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. State Medicaid Programs to Spend $1.6 Trillion on Long-Term Care over the Next Twenty Years
2. Twenty of Americas Most Promising Scientists Selected as 2008 Pew Scholars in the Biomedical Sciences
3. MAP Pharmaceuticals to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
4. BD to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
5. Medco CEO to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
6. ev3 Inc. to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
7. Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008
8. Twenty-Five Individuals Honored by Yoplait(R) for Making Extraordinary Strides in the Fight Against Breast Cancer
9. The American Liver Foundation Appoints Rick Smith, a Twenty-Year Veteran of The MS Society, as Chief Executive Officer
10. Top Twenty Health Plan Websites Named by TheRatingsGuy.com
11. Memory Pharmaceuticals Announces Six Abstracts Accepted for Presentation at Society for Neuroscience Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... NC (PRWEB) May 26, 2015 ... compliance solutions for the health and human services market, ... to meet demand. After strong attendance and participation in ... groups, and give their annual user conference an exciting ... Relias customers to come together and discuss best practices, ...
(Date:5/26/2015)... May 26, 2015 Mr. Larry Westenberg ... expert in Neuro-Linguistic Programming, or NLP. Mr. Westenberg ... Rapid Resolution Therapy® or RRT®. While many people ... and applied it to specific areas, Mr. Westenberg has ... for over 20 years. He works with people ...
(Date:5/26/2015)... Santa Rosa, CA (PRWEB) May 26, 2015 ... Management and Analytics solutions for more than 15 years, ... from the National Committee for Quality Assurance (NCQA) for ... today. , “We are proud of the work we ... years and are grateful for the acknowledgement from NCQA ...
(Date:5/26/2015)... Pass, OR (PRWEB) May 26, 2015 ... always fatal if not caught early. Melanoma is also ... water advocate Sharon Kleyne, the melanoma rate is on ... radiation. While the melanoma risk for indoor tanning salon ... these establishments. The most recent ban, in Pennsylvania, coincides ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Writers ... Editor with the Vasont® CCMS to make creating, ... Systems, a top component content management system (CCMS) ... (VUI) extension supports oXygen XML Editor Version 17.0, ... Vasont Universal Integrator extension merges key editorial functionality ...
Breaking Medicine News(10 mins):Health News:Relias Learning Expands User Groups and Industry Influence 2Health News:Relias Learning Expands User Groups and Industry Influence 3Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 2Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 3Health News:Skin Cancer Awareness Month: Pennsylvania Ban of Teens from Tanning Salons Is Praised by Fresh Water Advocate Sharon Kleyne 2Health News:Skin Cancer Awareness Month: Pennsylvania Ban of Teens from Tanning Salons Is Praised by Fresh Water Advocate Sharon Kleyne 3Health News:Vasont Systems Certifies the Integration between the Vasont® Component Content Management System and oXygen® XML Editor 17.0 2
... changes and inflammation has been awarded a Wellcome Trust ... The research programme at the National Institute for Health ... Professor Julian Davis, a consultant endocrinologist at Manchester Royal ... Biomedicine Research Group. He is working with Professor ...
... the Walter and Eliza Hall Institute in Melbourne, Australia, has ... further research into an aggressive and highly lethal form of ... the cell lining (epithelium) of the ovary, accounts for 90 ... still poorly understood, and recent research has revealed that it ...
... TUESDAY, Oct. 26 (HealthDay News) -- New research challenges previous ... with a certain genetic mutation. While guidelines have recommended ... their KRAS gene should not receive the targeted ... of these patients might actually benefit from taking the drug. ...
... , TUESDAY, Oct. 26 (HealthDay News) -- ... physicians, and this may be one reason for U.S. ... new study. Researchers looked at the wages of ... them into four broad categories: primary care; surgery; internal ...
... School of Medicine and The Children,s Hospital have taken a ... serious liver diseases in infants. The disease is called ... through which bile, crucial for digestion, flows to the small ... one in 10,000 births. But it,s life-threatening. "It ...
... In the 15 minutes a primary care doctor typically ... ailment, help manage ongoing health issues and provide preventive care. ... immediate mental health needs of patients is an ongoing challenge. ... Michigan Health System, however, points to an encouraging strategy for ...
Cached Medicine News:Health News:Manchester team wins $1.9 million grant for 'cell control' study 2Health News:VCA fellowship funding to extend ovarian cancer research 2Health News:New Insights on Who Should Take Erbitux for Colon Cancer 2Health News:Primary Care MDs at Low End of Pay Scale, Study Finds 2Health News:Breakthrough in understanding life-threatening childhood liver disease 2Health News:Follow-ups prove powerful tool for treating depression in primary care 2
(Date:5/26/2015)... , May 26, 2015  MGC Diagnostics Corporation (NasdaqCM: MGCD), ... to discuss its financial results for the second quarter of ... at 4:30 p.m. ET on Tuesday, June 2, 2015. The ... fiscal 2015 at the close of the markets on Tuesday, ... 317-6789 or (412) 317-6789 to access the conference call, or ...
(Date:5/26/2015)... Boehringer Ingelheim today announced that the ... STIOLTO™ RESPIMAT ® (tiotropium bromide and olodaterol) ... long-term, once-daily maintenance treatment of airflow obstruction in ... chronic bronchitis and/or emphysema. STIOLTO RESPIMAT is not ... COPD. COPD, which includes chronic bronchitis ...
(Date:5/26/2015)... 2015 Mast Therapeutics, Inc. ... its molecular adhesion and sealant technology (MAST) platform ... heart failure, and arterial disease, today reported that ... extension study of vepoloxamer (MST-188) in sickle cell ... enroll patients who have completed the Company,s Phase ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2015 Financial Results on Tuesday, June 2, 2015 2FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 2FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 3FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 4FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 5FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 6FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 7FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 8FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 9FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 10FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 11FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 12FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 13Mast Therapeutics Announces Initiation Of EPIC-E Study 2Mast Therapeutics Announces Initiation Of EPIC-E Study 3Mast Therapeutics Announces Initiation Of EPIC-E Study 4Mast Therapeutics Announces Initiation Of EPIC-E Study 5
... 15, 2011 Pharmaceutical companies are dramatically increasing ... meet the demands of a patient-empowered, data-driven, outcomes-focused ... alone, pharmaceutical company investment in smart phone apps, ... other programs increased 78%, as companies embrace a ...
... Unilife Corporation ("Unilife" or "Company") (Nasdaq: ... the three and six months ended December 31, 2010 (Fiscal ... Completed, on-schedule, the construction of a new ... staff now working out of the new facility ...
Cached Medicine Technology:Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 2Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 3Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 4Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 5Unilife Corporation Announces Financial Results For Fiscal Year 2011 Second Quarter 2Unilife Corporation Announces Financial Results For Fiscal Year 2011 Second Quarter 3Unilife Corporation Announces Financial Results For Fiscal Year 2011 Second Quarter 4Unilife Corporation Announces Financial Results For Fiscal Year 2011 Second Quarter 5Unilife Corporation Announces Financial Results For Fiscal Year 2011 Second Quarter 6Unilife Corporation Announces Financial Results For Fiscal Year 2011 Second Quarter 7
The flexible nature of the vinyl allows the user to reach deeper into the chamber and allows for a greater comfort when working inside the glove box over a long period of time compared to any rigid s...
This chamber is designed to provide a large workspace and gloveless dexterity in closed environment industrial, research and development, quality control packaging applications. Atmospheres of nitrog...
... MACS MICS is a fast, ... mixtures for growth of microaerophilic organisms.Designed ... jar-based MACS MICS runs at 1% ... envelopes and is suitable for growth ...
The airlock allows anaerobic entry of large flasks, vessels, and up to 90 plates at a time....
Medicine Products: